Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 5,407

Document Document Title
WO/1999/043659A1
A process for producing a pyridone derivative represented by general formula (4), characterized by reacting a compound represented by general formula (1) with a hypochlorite or hypobromite or with lead tetraacetate to give a compound rep...  
WO/1999/043663A1
NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.  
WO/1999/042452A1
Phthalazine derivatives represented by general formula (I) or pharmacologically acceptable salts thereof or hydrates of the same usable as remedies for erectile dysfunction, wherein R¿1? and R¿2? are the same or different and each repr...  
WO/1999/042449A1
Nitrogen compounds represented by formula (XXIa) or (XXIb); an epoxy resin hardening accelerator and a resin composition each containing any of the compounds; and an electronic part device containing an element encapsulated with the comp...  
WO/1999/042461A1
Quinoxaline compounds are described as well as method for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated dis...  
WO/1999/042463A1
Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated di...  
WO/1999/041250A1
1,4-Dihydropyridine derivatives represented by general formula (I) and antagonists against tolerance to anticancer drugs or anticancer drug potentiators containing as the active ingredient these derivatives, pharmacologically acceptable ...  
WO/1999/041235A1
The present invention relates to a compound of formula (1) wherein A is of formula (2), (3), (4), B is phenyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, thienyl, thiazolyl, furyl or oxazolyl, the ring being substituted on ring carbon a...  
WO/1999/041244A1
The present invention provides novel substituted aminophenyl isoxazoline derivatives of formula (I), wherein R¿1? is H, alkyl, cycloalkyl, alkoxy, amino, or alkylamino; X and Y are the same and different and are H, F, or CH¿3?; W is O,...  
WO/1999/041253A1
Compounds and compositions which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives having formula (I) wherein X is a member selected f...  
WO/1999/040025A1
The invention concerns novel ionic compounds with low melting point whereof the onium type cation having at least a heteroatom such as N, O, S or P bearing the positive charge and whereof the anion includes, wholly or partially, at least...  
WO/1999/040075A1
Compounds represented by general formula (I) or salts thereof and prodrugs of the same which have an inhibitory effect on activated blood coagulation factor X and thus are useful as anticoagulating agents. In formula (I), R?1¿ represent...  
WO/1999/038514A1
The present invention is directed to cyclic amines of formula I (wherein R?1¿, R?2¿, R?3¿, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulat...  
WO/1999/038844A1
The present invention relates to a method for preparing an N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound of formula (I) wherein R¿a? is (II); R¿aa? is hydrogen, optionally substituted aliphatic or optionally substituted...  
WO/1999/037625A1
Compounds are provided having formula (I), wherein R, R¿1?, R¿2?, R¿3? and R¿4? are defined in the specification, which have matrix metalloproteinase inhibiting activity.  
WO/1999/037637A1
A compound of formula (I) wherein A is an optionally substituted heterocyclic group; R is a lower alkoxy; Z is C=O or CH¿2?; and B is a saturated or unsaturated condensed ring group selected from the group consisting of benzazepinyl, be...  
WO/1999/033460A1
Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have structure (I) wherein n is 1 to 5; X is N or C-R?5¿ wherein R?5¿ is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R?1¿, R?2Â...  
WO/1999/033781A1
Compounds represented by formulae (I, II or III), wherein U is CH, O, or S; Z is -C(R¿2?)(R¿3?), -CH-N(R¿2?)(R¿3?), C(R¿3?)[(CH¿2?)nR¿2?], CH-C(R¿3?)(R¿8?)(CH¿2?)nR¿2?, C[(CH¿2?)nR¿2?]-[CH(R¿3?)(R¿8?)], C[(R¿3?)][CH[(CH¿...  
WO/1999/032109A1
The present invention concerns novel paclitaxel derivatives, their use as antitumor agents, and pharmaceutical formulations.  
WO/1999/032468A1
This invention is provide a compound of formula (I) wherein R?1¿ is an optionally substituted 5- to 6-membered ring; W is a divalent group of formula (a) or (b) wherein the ring A is an optionally substituted 5- to 6-membered aromatic r...  
WO/1999/032460A1
The invention relates to inventive compounds of formula (I), wherein R?1¿, R?2¿, R?3¿ and Ar have the meanings cited in the claims. The inventive compounds are suitable for use in the production of medicaments, e.g. for prophylaxis an...  
WO/1999/032106A1
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.  
WO/1999/032446A1
A dihydropyridine derivative represented by formula (I), analogues thereof and medicinally acceptable salts of both exhibit a selective blocking activity against N-type calcium channel, and are therefore useful as therapeutic agents for ...  
WO/1999/032464A1
Compounds of formula (I) and process for protecting and immunizing plants against attack by phytopathogenic microorganisms by applying compounds of formula (I) wherein a) X is CR¿4? and Y is N; or b) X is N and Y is CR¿5?; or c) X and ...  
WO/1999/031073A1
Pyrimidine-5-carboxyamide derivatives represented by general formula (I) or salts thereof, wherein each symbol has the meaning as specified below: X: O, S, NR?1¿, CO, NR?1¿CO, CONR?1¿, C=N-OR?1¿ or a bond; Y: lower alkylene optionall...  
WO/1999/031077A1
A series of arylpiperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1¿A? receptor; the compounds are particularly effective antagonists at that receptor, and are par...  
WO/1999/031037A1
Apoptosis inhibitors containing as the active ingredient compounds represented by general formula (I) or salts thereof, wherein W¿1? represents -O-, -CH¿2?-, etc.; W¿2? represents -CH¿2?-, etc.; W¿3? represents -O-, -CH¿2?-, etc.; ...  
WO/1999/029671A1
Benzoic acid derivatives of general formula (I), wherein the substituents have the meanings cited in the description.  
WO/1999/029674A1
The present invention is concerned with compounds of formula (I) the $i(N)-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR?3¿; R?1¿ represents hydr...  
WO/1999/029660A1
The invention provides adamantane derivatives represented by formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In...  
WO/1999/029676A1
Process for the preparation of a compound of formula (VIII) wherein R¿1? is Cl, F or CF¿3?; R¿2? is H, Cl, F or CF¿3?; and R¿3? is C¿1-4? alkyl; characterized in that a triol of formula II is treated with a ketone or an aldehyde to...  
WO/1999/029647A1
Apoptosis inducers represented by chemical formulae (I), (II), (VIII), (IV), (V), (VI), (III) and (VII); and medicinal compositions containing the same and usable as carcinostatic and the like.  
WO/1999/029675A1
Process for the preparation of a compound of formula (VII) wherein R¿1? is Cl, F or CF¿3?; R¿2? is H, Cl, F or CF¿3?; and R¿3? is C¿1-4? alkyl; characterized in that an olefin of formula (II) is epoxidized to give an oxirane of for...  
WO/1999/028309A1
Compounds of formula (I) wherein m is zero or 1; Q represents a C¿6?-C¿14? aromatic ring system or an optionally substituted, saturated or unsaturated, heteromonocyclic or heterobicyclic ring containing one or two heteroatoms chosen fr...  
WO/1999/028292A1
The invention concerns ionic compositions with high ionic conductivity, comprising a salt with delocalized anionic charge. An ionic composition comprises a salt dissolved in a solvent and has a conductivity higher than 10?-5¿ S.cm?-1¿ ...  
WO/1999/028282A1
A process for preparing a compound of Formula (I); where Q completes an optionally substituted 5- or 6-member saturated carbocyclic ring and R is optionally substituted phenyl or optionally substituted C¿3?-C¿6? cycloalkyl which proces...  
WO/1999/026927A2
The present invention provides compounds, and pharmaceutical compositions containing those compounds, that act as antagonists at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders....  
WO/1999/026933A1
The present invention relates to novel biheterocyclic derivatives which are factor Xa inhibitors; the pharmaceutically acceptable salts and $i(N)-oxides thereof; their uses as therapeutic agents and the methods of their making.  
WO/1999/026932A1
The present invention relates to novel biheterocyclic derivatives which are factor Xa inhibitors; the pharmaceutically acceptable salts and $i(N)-oxides thereof; their uses as therapeutic agents and the methods of their making.  
WO/1999/025687A1
A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-...  
WO/1999/024425A1
Compounds represented by general formula (I) and having both an IL-4 production inhibitory activity and a PDE(IV) inhibitory activity; a medicinal composition comprising an effective amount of any of the compounds and a pharmaceutical ca...  
WO/1999/024393A1
The present invention includes a number of novel intermediates such as the (S)-secondary alcohol of formula (VIIIA) X¿2?-CH¿2?-C*H(OH)-CH¿2?-NH-CO-R¿N? and processes for production of pharmacologically useful oxazolidinones.  
WO/1999/024420A1
A group of novel pyrimidone compounds are inhibitors of the enzyme LDL PLA2 and therefore of use in treating atherosclerosis.  
WO/1999/023069A1
Compounds represented by general formula (1), having NOS inhibitory activities, and being useful as medicines such as a remedy for cerebrovascular disorder, wherein R¿1? represents aminoalkyl, etc.; R¿2? represents hydrogen, lower alky...  
WO/1999/023079A1
The invention relates to compounds of formula (I) or the salts thereof, wherein R?1¿, R?3¿ = H, (substituted) hydrocarbon radical (KW) or (substituted) heterocyclyl, which comprise inclusive substituents 1-30 C-atoms, R?2¿ = R?0¿-Q?0...  
WO/1999/021838A1
The 2-[2-(3,5-dichlorophenyl)ethyl]benzoic acid (V) which is the key intermediate for the preparation of eberconazol (I) through a known sequence of four steps is prepared by catalytic hydrogenation of 2-[2-(3,5-dichlorophenyl)ethenyl]be...  
WO/1999/021845A2
This invention is directed to aminothiazole compounds of formula (I) wherein R?1¿ is a substituted or unsubstituted group selected from: C¿1-6?-alkyl; C¿1-6?-alkenyl; C¿1-6?-alkynyl; C¿1-6?-alkoxyl; C¿1-6?-alcohol; carbocyclic or h...  
WO/1999/020608A1
Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein one of R?1¿ and R?2¿ is H and the other is N=C(NH¿2?)¿2? or NHC(=NH)NH¿2?, and the other substituents are as defined herein, are urokinase (uPA) inhibit...  
WO/1999/020269A1
Carbapenems substituted with a naphthosultam at position 2 and linked through a CH¿2? group are disclosed. Pharmaceutical compositions and methods of treatment are also included. The naphtosultam is substituted with at least one cationi...  
WO/1999/020611A1
The present invention relates to compound of formula (1), wherein Ar?1¿ represents (A), or (B), or (C); R?12¿ and R?13¿ are independently hydrogen or C¿1-4? alkyl; Ar?2¿ is phenyl or heteroaryl; p is 0 or 1; Ar?3¿ is phenyl, pyridi...  

Matches 651 - 700 out of 5,407